Abstract Purpose of Review Discontinuation of tyrosine kinase inhibitors (TKIs) in chronic
phase chronic myeloid leukemia (CP-CML) patients has become a reality. Treatment-free …

Introduction: With the discovery of imatinib mesylate nearly 20 years ago, tyrosine kinase
inhibitors (TKIs) were found to be effective in chronic myeloid leukemia (CML). TKI therapy …

Hematological malignancy during pregnancy is a rare event, therefore most data on this
issue is based on case studies, retrospective studies and expert opinion. The purpose of the …

Introduction: Despite the advent of molecular assessment, banding cytogenetics and
fluorescence in situ hybridization (FISH) still have a significant role in diagnostic and …

Background: Immunotherapy utilizing T cells genetically modified to express chimeric
antigen receptors (CARs) is rapidly emerging as a promising novel treatment for …

Chronic myeloid leukemia (CML) is rare in children but presents a unique challenge as
recent drug innovations have turned CML into a chronic disease with implications for …

Fast identification of BCR-ABL fusion genes is critical for precise diagnosis, risk stratification
and therapy scheme selection in leukemia. More convenient methods are needed for quickly …

Chronic myeloid leukemia (CML) is characterized by expression of the tyrosine kinase
oncogene, Bcr–abl. Tyrosine kinase inhibitors (TKI) induce prolonged remission in CML …

The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

A single-center retrospective was performed with consecutive de novo BCR-ABL1-positive
acute lymphoblastic leukemia (ALL) patients who received TKI-containing therapy between …